If a patient with advanced epithelial ovarian cancer (EOC) lives without disease progression for 10 years after diagnosis, they are considered to be cured. Researchers describe the percentage of patients with Stage III EOC who achieved LTDFS (long-term disease-free survival ≥10 years) after receiving intraperitoneal (IP) or intravenous (IV) chemotherapy, as well as the factors that predicted LTDFS. Information on demographics, clinicopathologic characteristics, routes of administration, and survival outcomes of patients who lived more than or equal to 10 years as measured by the Kaplan-Meier technique was evaluated from 3 completed NRG/GOG studies (n=104, 114, 172). Cox, proportional hazards modeling, was used to assess the univariate determinants of LTDFS. Overall survival (OS) at 10 years was 26% (95% CI, 23-28%) among the 1,174 randomly selected patients, while LTDFS at 10 years was 18% (95% CI, 16-20%). The median age for patients with LTDFS older than or equal to 10 years was 54.6 (P<0.001). Multivariate Cox analysis found that younger age was the only independent predictive predictor for LTDFS more than or equal to 10 years (P<0.001). About 18% of patients had LTDFS of 10 years or less. They represent the very last of the survivors and are, most likely, cured. Investigators findings establish a benchmark for assessing the effect of PARP inhibitors on survival outcomes in 1st-line maintenance studies.

Source: sciencedirect.com/science/article/pii/S009082582200436X